drugset

drugset / Trial / NCT01444404

A Study of AMG 820 in Subjects With Advanced Solid Tumors

NCT01444404 ↗

Phase 1 Completed 25 enrolled AmMax Bio, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.

Timeline

Start: 2008-03-31
Primary completion: 2014-02-06
Completion: 2014-02-06

Publications

Background Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMG 820	Monoclonal antibody	—	—

Indications